June 24, 2020 / 6:28 PM / 16 days ago

BRIEF-AstraZeneca Says Breztri Aerosphere Significantly Reduced Rate Of Moderate Or Severe COPD Exacerbations In Phase III Ethos Trial

June 24 (Reuters) - AstraZeneca PLC:

* BREZTRI AEROSPHERE SIGNIFICANTLY REDUCED RATE OF MODERATE OR SEVERE COPD EXACERBATIONS IN PHASE III ETHOS TRIAL

* ASTRAZENECA - SAFETY AND TOLERABILITY OF BREZTRI AEROSPHERE WERE CONSISTENT WITH KNOWN PROFILES OF DUAL COMPARATORS

* ASTRAZENECA - IN KEY SECONDARY ENDPOINT, BREZTRI AEROSPHERE SHOWED 46% REDUCTION IN RISK OF ALL-CAUSE MORTALITY COMPARED WITH BEVESPI AEROSPHERE

* ASTRAZENECA - INCIDENCE OF CONFIRMED PNEUMONIA WAS 4.2% WITH BREZTRI AEROSPHERE, 2.3% WITH BEVESPI AEROSPHERE AND 4.5% WITH PT009

* ASTRAZENECA - IN TRIAL, MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE NASOPHARYNGITIS, COPD AND UPPER RESPIRATORY TRACT INFECTION

* ASTRAZENECA -UNDER DEAL TO BUY PEARL THERAPEUTICS, SEES MAKING $150M MILESTONE PAYMENT UPON US REGULATORY APPROVAL OF BREZTRI AEROSPHERE FOR COPD Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below